Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma.
In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,
Welcome to CancerFax !
CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.
Let us know what we can do for you.
1) Cancer treatment abroad? 2) CAR T-Cell therapy 3) Cancer vaccine 4) Online video consultation 5) Proton therapy